Knowledge Hub

​In-depth Analysis and Forecast Of The Osteoarthritis Market 2024 On The Global As Well As Regional Level

Press release   •   Jul 27, 2017 05:52 EDT

About Osteoarthritis Market

Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. The disease is caused by the breakdown of the joint cartilage due to mechanical stress or biochemical alterations, which causes the bone underneath to fail. OA can occur together with other types of arthritis, such as gout or rheumatoid arthritis (RA). OA tends to affect commonly used joints such as the hands and spine as well as the weight-bearing joints such as the hips and knees. The causes of OA are not fully understood. However, genetic factors, and damage to the joints, either through repeated excessive loading and stress of a joint over time (for example, the knee joint in an obese person) or by injury (such as a break or dislocation of a finger joint) increases the risk of developing OA. There is no single test to diagnose OA. Several methods are used to diagnose OA and to rule out other problems: medical history, physical exam, X-rays, blood tests, or joint fluid analysis. The structural changes that occur with old age may not be accompanied by symptoms, which makes the estimation of the prevalence of OA difficult.

Scope

- Overview of OA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized OA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the OA therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global OA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/879202

Table of Contents

1 Table of Contents 10

1.1 List of Tables 14

1.2 List of Figures 18

2 Introduction 19

2.1 Catalyst 19

2.2 Related Reports 20

3 Disease Overview 21

3.1 Etiology and Pathophysiology 21

3.1.1 Etiology 21

3.1.2 Pathophysiology 24

3.2 Symptoms 26

4 Epidemiology 27

4.1 Disease Background 27

4.2 Risk Factors and Comorbidities 28

4.3 Global and Historical Trends 30

4.3.1 Total Prevalence of OA - 7MM 30

4.3.2 Diagnosed Prevalence of OA - 7MM 30

4.3.3 US 31

4.3.4 5EU 31

4.3.5 Japan 32

4.4 Forecast Methodology 34

4.4.1 Sources Used 42

4.4.2 Sources Not Used 47

4.4.3 Forecast Assumptions and Methods 48

4.5 Epidemiological Forecast for OA (2014-2024) 53

4.5.1 Total Prevalent Cases 53

4.5.2 Diagnosed Prevalent Cases 70

4.5.3 Severity of Knee OA Based on KL Grades 86

4.6 Discussion 87

4.6.1 Epidemiological Forecast Insight 87

4.6.2 Limitations of the Analysis 88

4.6.3 Strengths of the Analysis 89

5 Current Treatment Options 90

5.1 Overview 90

5.2 Product Profiles - Major Therapies 92

5.2.1 NSAIDs (Numerous Branded and Generic Products) 92

5.2.2 Topical Therapies (Numerous Branded and Generic Products) 96

5.2.3 Opioids (Numerous Branded and Generic Products) 101

5.2.4 Antidepressants (Numerous Branded and Generic Products) 106

5.2.5 Intra-Articular Corticosteroid Injections (Numerous Branded and Generic Products) 108

View Report @ https://www.marketresearchreports.biz/reports/879202/opportunityanalyzer-osteoarthritis-opportunity-analysis-and-forecasts-to-2024-market-research-reports

6 Unmet Needs Assessment and Opportunity Analysis 112

6.1 Overview 112

6.2 Analgesic Drugs that Adequately Address Pain 113

6.2.1 Unmet Need 113

6.2.2 Gap Analysis 114

6.2.3 Opportunity 114

6.3 Disease-Modifying Drugs 115

6.3.1 Unmet Need 115

6.3.2 Gap Analysis 116

6.3.3 Opportunity 116

6.4 Drugs with Improved Tolerability for Use in the Elderly Patient Population 116

6.4.1 Unmet Need 116

6.4.2 Gap Analysis 117

6.4.3 Opportunity 117

6.5 Improved Implementation of Guidelines on Non-pharmaceutical Treatments 117

6.5.1 Unmet Need 117

6.5.2 Gap Analysis 118

6.5.3 Opportunity 119

6.6 Early Detection and Intervention 119

6.6.1 Unmet Need 119

6.6.2 Gap Analysis 120

6.6.3 Opportunity 120

7 Research and Development Strategies 121

7.1 Overview 121

7.2 Development of Pharmacological Treatments with Novel MOAs 121

7.3 Development of Disease-Modifying OA Drugs 122

7.4 Strategic Partnerships 123

7.5 Current Clinical Trial Design 124

7.5.1 Limitations of Patient-Reported Outcomes 125

7.5.2 Lack of Useful Subpopulations for Targeted Therapies 125

7.5.3 Lack of Consensus on DMOAD Trial Design 126

7.6 Future Clinical Trial Design 127

7.6.1 Sensitive Measurement Tools for Evaluating Joint Morphology 127

7.6.2 Developing and Qualifying Biomarkers to Enable DMOADs Development 127

7.6.3 Future Trials Need to Take into Consideration Joint Tissues Other Than Articular Cartilage 128

Send An Enquiry Request @

https://www.marketresearchreports.biz/sample/enquiry/879202

8 Pipeline Assessment 129

8.1 Overview 129

8.2 Promising Drugs in Clinical Development 130

8.2.1 Ampion 130

8.2.2 NKTR-181 134

8.2.3 FX006 (Zilretta) 137

8.2.4 Anti-NGF 140

8.2.5 Invossa 147

8.2.6 Sprifermin 152

8.3 Innovative Early-Stage Approaches 156

8.3.1 Targeting Innovative Pain Signaling Pathways 158

8.3.2 Pro-inflammatory Cytokine Modulation 159

8.3.3 Growth Factor Therapy 160

8.3.4 Subchondral Bone Remodeling 160

9 Pipeline Valuation Analysis 162

9.1 Clinical Benchmarking of Key Pipeline Drugs 162

9.2 Commercial Benchmark of Key Pipeline Drugs 163

9.3 Competitive Assessment 165

9.4 Top-Line 10-Year Forecast 166

9.4.1 US 168

9.4.2 5EU 170

9.4.3 Japan 171

10 Appendix 173

10.1 Bibliography 173

10.2 Abbreviations 188

10.3 Methodology 192

10.4 Forecasting Methodology 192

10.4.1 Diagnosed OA Patients 192

10.4.2 Percent Drug-Treated Patients 193

10.4.3 Drugs Included in Each Therapeutic Class 193

10.4.4 Launch and Patent Expiry Dates 194

10.4.5 General Pricing Assumptions 194

10.4.6 Individual Drug Assumptions 195

10.4.7 Generic Erosion 201

10.4.8 Pricing of Pipeline Agents 201

10.5 Physicians and Specialists Included in this Study 203

10.6 Primary Research-Prescriber Survey 204

10.7 About the Authors 205

10.7.1 Author 205

10.7.2 Epidemiologist 205

10.8 About GlobalData 206

10.9 Disclaimer 206

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.